Pippa Hutchison. Executive Director of the International Aspirin Foundation. International Aspirin Foundation Scientific Advisory Board
|
|
- Baldwin Wood
- 5 years ago
- Views:
Transcription
1 International Aspirin Foundation Senior Science Award Ceremony 2016
2
3 Pippa Hutchison Executive Director of the International Aspirin Foundation Pippa welcomed the attendees and introduced the Senior Science Awards evening which, this year, honours the work of three world class Professors from Boston, Massachusetts for their dedication to aspirin research. The Foundation began in 1974 with the aim of increasing the knowledge and understanding of aspirin and owes its existence to the vision of Nick Henderson. Nick remains active as President of the Foundation and sent his best wishes to the winners and attendees of the awards evening. Pippa announced that Tom Smith, the Foundation s medical writer, is stepping down after many years of dedicated service. He is passing the role to Jaqui Walker (GPN and medical writer) and the executive team has been further strengthened with the addition of Laura Sutherland in PR & communications and Douglas Hutchison as a fellow director. In her opening speech Pippa highlighted the importance of aspirin, explaining that the World Health Organisation (WHO) classifies aspirin as an essential medicine (one that is needed to satisfy the priority healthcare needs of the population) due to the value aspirin has made to human health; its ease of use and its low cost. The Scientific Meeting and presentation of the Senior Science Award not only honours the significant contribution that this year s winners have made to research into the role of aspirin, but aims to encourage and stimulate future work into aspirin s potential, as it continues to surprise with new important indications for use within healthcare. The International Aspirin Foundation continues to have ambitious plans and attracts international interest. At the award ceremony Pippa welcomed visitors from North America, China and Europe. In September 2017, the Foundation will hold a special scientific conference in Berlin to celebrate 120 years since the synthesis of acetylsalicylic acid. The International Aspirin Foundation is also extremely honoured to be guided by a Scientific Advisory Board of international key opinion leaders whose Chair, Peter Rothwell, introduced the Scientific Meeting and presented the Senior Science Award. International Aspirin Foundation Scientific Advisory Board
4 Professor Rothwell noted that the award was incredibly well deserved and presented the Professors with their award which included a framed certificate and a pair of crystal tumblers engraved with the crest of the International Aspirin Foundation.
5 Professor Peter Rothwell Chair of the Scientific Advisory Board of the International Aspirin Foundation Professor Rothwell introduced the scientific meeting and gave a speech on behalf of Professor Peter Elwood (who was unable to attend) on the history of both the Senior Science Award and the origins of aspirin. The Senior Science Award is a very prestigious award that aims to recognise and support contributions to aspirin research and development from around the globe. The award has an impressive pedigree of previous winners who have all made significant contributions to the development of aspirin. The winners of this years award are Professor Julie Buring, Professor Michael Gaziano and Professor Nancy Cook for their work to increase the understanding of the role of aspirin as a preventative strategy in both cardiovascular disease (CVD) and for certain cancers. Presentations by both Professor John Michael Gaziano and Professor Nancy Cook later in the evening described this work in more depth. Julia Buring is Professor of Medicine in the Division of Preventative Medicine at Brigham and Women s Hospital and Harvard Medical School. The main focus of her research has been on the epidemiology of chronic diseases such as CVD and cancer in women. She is principle investigator (PI) on the Women s Health Study (WHS) and its observational follow up and showed the vision to develop the cohort into a rich resource of phenotypic, biomarker and genetic data which has benefited many other studies. Professor Rothwell took the attendees back in time to the first recorded use of plants containing salicylate (the natural component that aspirin is derived from) such as willow, meadowsweet and cumin. This fascinating historical journey moved the audience through ancient times when salicylates use for pain and fever was discovered, with for example the Egyptians in 1500 BC, Hypocrates 300 BC, to a 1763 letter to the Royal Society by The Revd Edward Stone describing its use for rheumatic fever. We moved forward to the acetylation of aspirin in the mid to late 1800s which led to its launch by Bayer at the turn of the century. Next the seminal trials of the sixties and seventies were discussed, these trials showed the role of aspirin as an antithrombotic and paved the way for the long term prevention studies that are now influencing the recommendations in prevention guidelines today. The Food and Drug Administration (FDA) gave approval for the use of aspirin to reduce the risk of stroke after transient ischaemic attack (TIA) in 1980 and as a preventative post myocardial infarction (MI) in The work of Peter Elwood, Charles Warlow, Richard Doll and Richard Petro in the prophylactic use of aspirin for preventing CVD events led on to the development in the USA of the Physicians Health Study and Women s Health Study the data from which has led to the wider ranging guidance for aspirin in primary prevention of both CVD and colorectal cancer (CRC).
6
7 Professor J Michael Gaziano Professor of Medicine at Harvard Medical School, Chief of the Division of Aging at Brigham and Women s Hospital and Principal Investigator, Million Veteran Program, VA Boston Healthcare System in Boston Professor Gaziano has a significant clinical practice, runs a major academic department and is a world renowned researcher on the epidemiology of vascular disease, large-scale clinical trials and preventative cardiology. Professor Gaziano expressed his honour to be at the awards meeting with Nancy Cook and on behalf of Julie Buring who have between them led the Boston teams responsible for the two largest randomised controlled trials to look at the impact aspirin has in the prevention of CVD and other pathologies (e.g. cancer). Professor Gaziano reviewed both the history and the future direction of what he described as the spectacular opportunity presented by these two population studies: Physicians Health Study (PHS) Women s Health Study (WHS) Professor Gaziano commenced and concluded his presentation with a patient with multiple risk factors and asked the audience to reflect upon whether or not this patient should be given aspirin. He emphasised the importance of ensuring prevention studies have a focus on the patient and the use of the intervention in real life. Patient with Multiple Risk Factors for CVD 56-year-old male No history of CVD or diabetes Father died at age 45 of MI Nonsmoker BP: 144/89 mm Hg (treated) BMI 28 Lipid parameters > Total cholesterol: 243 mg/dl > LDL-C: 172 mg/dl > HDL-C: 39 mg/dl > Triglycerides: 158 mg/dl Should he be on ASA? What is his CVD Risk?
8 His presentation took the audience through the story of aspirin in preventative medicine but also looked at the important role aspirin has played in the evolution of epidemiology trials. He divided clinical trial development into four stages: > Descriptive phase - which is about numbers > Pre-analytic phase- when associations are made > Analytic phase - case control studies, cohort studies, RCTs > Super analytic phase - mega biobanks, genetics, phenotype, environment There are over 400 trials for the use of aspirin in secondary prevention working on the hypothesis that platelet inhibition with aspirin will lower the risk of subsequent vascular events in those with prior MI, stroke, CAD, TIA or peripheral artery disease. A collaboration of the results from these antithrombotic trials showed an overall 22% risk reduction in vascular events. This led on to the hypothesis that aspirin could potentially also prevent a first CVD event. The trials of aspirin in primary prevention were longer trials, the event rates are lower in this population and yet the complication rate (gastric bleeds) remains the same as for secondary prevention. The duration of time required for such a study is quite a challenge. The US Physicians Health Study (PHS) commenced in 1982 and continues today. It is a 2x2 factorial design, randomised, double-blind, placebocontrolled, observational cohort study. The trial recruited 22071, male physicians between the ages of years. The trial tested the effects of low dose aspirin (325mg on alternate days) in the primary prevention of CVD and beta-carotene (50mg on alternate days) in the prevention of cancer. Doctors were chosen because it was felt they could report events, consent and understand and complete forms by mail. A calendar pack of drugs taken on alternate days were sent out. Participants were proud to be part of such an important study and took photographs of themselves with their calendar packs from all around the globe. There has been excellent long term follow up. The results were very positive showing a 44% reduction in first MI due to aspirin. Death in old age is inevitable but death before old age is not. Richard Doll The US Women s Health Study (WHS) commenced in 1999 with a similar design. It enrolled 39876, female health professionals aged 45 years and over and its aim was to study the effect of alternate day low dose (100mg) aspirin and alternate day vitamin E (600mg). Like the PHS it was a postal study. MI in the Physicians Health Study number of MIs Placebo (n=11,034) 44% in the first MI due to aspirin 139 Aspirin (n=11,037) Professor Gaziano has also led progress in embedding research into health care systems by establishing the Massachusetts Veterans Epidemiology Research and Information Centre (MAVERIC) and is Director for the Million Veteran Program which will be important for future discovery in genetics and epidemiology. Work in large scale trials to look at aspirin in higher than average risk populations is ongoing. The ARRIVE trial looking at initial CVD events will finish this year and report in early The ASCEND trial looks at cardiovascular risk in patients with diabetes and ASPREE aims to reduce cardiovascular events in the elderly. Professor Gaziano summarised by explaining that in secondary prevention aspirin clearly prevents
9 further CVD events in a wide range of high risk patients with a low risk of haemorrhagic stroke and at a dose of mg daily. The US FDA has provided indications for acute and prior MI and stroke, angina, PVD or other forms of vascular disease. Primary prevention with aspirin is effective at reducing the risk of a major first CVD event among both men and women but it is also important to consider baseline risks and look carefully at the sort of patient profiles who would most benefit from primary prevention e.g. patients with multiple risk factors for CVD. Even though bleeding with aspirin is rare, in order to optimise the benefit to risk ratio of low dose aspirin therapy careful discussion needs to be had at a clinical level with the patient. He explained; The paradox with preventative medicine is that the patient will blame you for their GI bleed but won t thank you for the stroke or MI you have silently prevented. It is estimated aspirin has the potential to save hundreds of thousands of lives through primary and secondary prevention of CVD around the world each year. It may also help prevent cancer. Guidelines recommend low-dose aspirin in those with a 10- year CVD risk of 10% or more. At the end of his talk Professor Gaziano took us back to the patient profile and asked if we would put that patient on aspirin for prevention of a CVD event. The majority of the audience appeared to support this. Key discussion points. How to assemble the cohort and maintain commitment? Calendar packs helped but also a test period was used to check commitment. Professor Gaziano found willing to participate but only passed muster when it came to adhering to the trial protocol. He felt that you can achieve a longer connection by mail but you need to ensure that you are maximising compliance. It is important to remember that preventative therapy lowers risk but it doesn t totally eliminate the risk. There may also be a delay in the time to the first event. Professor Gaziano advised that preventative medicine presents a very different paradigm to managing acute situations. In prevention; you need to work with the person to empower them to own and control their disease, risk and lifestyle. It is important to explain short term risks and benefits as well as long term benefits such as cancer risk reduction. These long term benefits should be seen more as an extra bonus.
10
11 Professor Nancy R Cook Professor of Biostatistics in the Department of Medicine at Harvard Medical School and Professor of Epidemiology at Harvard School of Public Health Professor Cook described how observational cohort studies had indicated that aspirin may reduce cancer incidence, especially CRC. This was supported by several meta-analyses looking at cancer outcomes within trials of aspirin and cardiovascular disease, primarily conducted by Professor Rothwell. A low dose (75-300mg) of daily aspirin in a meta-analysis of three trials showed the impact on CRC was a latent effect emerging after 7-10 years. At this point Professor Cook was chief statistician for WHS which had cancer as one of its primary outcomes. In the WHS just under 40,000 women age 45 and over took 100mg of aspirin every other day. The active intervention for this study ended in 2004 with a median of 10 years follow up. The results showed no reduction in cancer at the end of the active intervention part of the study. However, after eight additional years of post-trial follow-up there was a statistically significant reduction in CRC in those that had been in the active arm of the study. This latent, post-trial effect has a hazard ratio of 0.57 and is highly significant, with a clear difference in effect over time. A similar effect is seen when looking at all GI cancers. Cook et al, Ann Intern Med 2013 Professor Cook used statistical modelling to ensure these results were not due to differences in the women opting in for long term follow-up, or for differing characteristics in the women taking aspirin post-trial. The modelling work also ensured that interventions such as colonoscopy or polyp removal did not influence the results. No differences were found. Reference Cook NR, Lee I-M, Zhang SM, Moorthy MV, Buring JE. Alternate-day low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159:77-85
12 Adverse events did occur but in low numbers. Appropriate weighting of the adverse bleeding events in relation to GI cancer, MI and Stroke suggested a small benefit overall, with a larger benefit among women over the age of 65 years. This work contributed to the current USPSTF recommendations for aspirin in primary prevention of CVD and CRC. Professor Cook concluded that to fully understand the role of aspirin as a preventative strategy in the general population, prediction models for adverse as well as beneficial effects are required. Aspirin may not be appropriate for everyone in general population due to the increased risk of modest bleeds including ulcers, increased medical expenses and reduced quality of life. Understanding and targeting those at higher risk of CVD and CRC may be an important first step in getting aspirin used in clinical practice and increasing benefit for primary prevention of CVD and GI cancers. Key discussion points. Confounding factors may strongly influence the results from observational studies. For example, those who have GI side effects may stop taking aspirin but these effects could be related to a GI cancer. Aspirin use is associated with behaviours that are both beneficial and with those that increase risk. Those who exercise, have a healthy diet, and/or a family history of CVD or CRC may be more likely to take aspirin. Compliance is a big issue; will we only ever get a small subset of the population compliant over ten years? While compliance in both the PHS and WHS trials was very high, in the general population it may be more of a problem to adhere to using aspirin in the long term. It is important to advise patient s how to improve compliance. A lot of people will need to take aspirin for a small number to benefit. It may be best to present aspirin use to patients as a way to delay events rather than total prevention. It is important to focus on the individual s risks of CVD and CRC as well as GI bleeds. Professor Cook emphasised; Julie E Buring Professor in the Department of Epidemiology at Brigham and Women s Hospital Division of Preventive Medicine and Professor of Medicine at the T.H. Chan School of Public Health, Harvard University. Risk benefit discussion with higher risk patients needs to be embedded into clinical care so that people can benefit from the disease prevention capabilities of aspirin.
13
14 International Aspirin Foundation Senior Science Award Ceremony Professor Peter Rothwell took the opportunity to ask questions and discuss both the Physicians Health Study and Women s Health Study trials in depth with the world class professors. The full interview with both Professor Mike Gaziano and Professor Nancy Cook lasts for 17 minutes and can be seen using the following link:
15 Every effort is made by The Aspirin Foundation to see that no misleading or inaccurate data, statement or opinion appear in this publication, the International Aspirin Foundation cannot be held responsible for any errors or for any consequences arising from the use of the information contained in this publication. For further information see
16 Photography by Ben Carpenter For further information please contact International Aspirin Foundation Bower House 34 Bower Mount Road Maidstone Kent ME16 8AU Tel: +44(0) Fax: +44(0)
Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationBayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationScience in the News - Aspirin 1. Story
Science in the News - Aspirin 1. Story People have known since ancient times that aspirin helps to reduce pain and high body temperature. But that is not all aspirin can do. It has gained important new
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationORIGINAL INVESTIGATION. Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study
ORIGINAL INVESTIGATION Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study Nancy R. Cook, ScD; Patricia R. Hebert, PhD; JoAnn E. Manson,
More informationA Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II
A Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II Presenter Disclosure Information Howard D. Sesso, ScD, MPH Relevant Disclosures:
More informationBayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the
More informationVoluntary and Community Sector
Voluntary and Community Sector VOLUNTEERS WEEK 1 ST 7 TH JUNE 2015 Volunteers Week is an annual celebration of the fantastic contribution millions of volunteers make across the UK. At Swale CVS we are
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More informationLandmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo
Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationConflicts of Interest: None. Aspirin, primary prevention and USPSTF. Primary prevention of ASCVD is important
Aspirin, primary prevention and USPSTF Presented by: Craig Williams, PharmD., BCPS., FNLA; February 2017 Conflicts of Interest: None Primary prevention of ASCVD is important Myocardial Infarction Incidence
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationCOMMUNITY HEALTH NEEDS ASSESSMENT IMPLEMENTATION STRATEGY
2016 COMMUNITY HEALTH NEEDS ASSESSMENT IMPLEMENTATION STRATEGY Table of Contents Introduction... 2 Executive summary... 2 University Care System s mission, vision, and values... 2 Description of the health
More informationChest Heart & Stroke Scotland Research Strategy
Chest Heart & Stroke Scotland Research Strategy 2018-2021 Introduction Everyone has the right to live life to the full. After a diagnosis of a chest or heart condition or a stroke, many people experience
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationSponsorship opportunities
The National Autistic Society s Professional Conference and Autism Professionals Awards Tuesday 7 and Wednesday 8 March 2017 Harrogate Sponsorship opportunities www.autism.org.uk/conferences/professional2017
More informationBayer s Xarelto (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Secondary Prevention of Acute Coronary Syndrome (ACS): Bayer s Xarelto (Rivaroxaban)
More informationASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes
ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes Jane Armitage and Louise Bowman on behalf of the ASCEND
More informationEMBARGO: 08:30 Central European Summer Time Tuesday 29th August 2017
ANACETRAPIB REDUCES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS AMONG HIGH-RISK PATIENTS ON INTENSIVE STATIN TREATMENT Barcelona, Tuesday 29 August 2017: Anacetrapib, an inhibitor of Cholesteryl Ester Transfer
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationTargeting the High-Risk Patient
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationFamous Things ESL lesson plans from ESL-Images.com
PRE-READING QUESTIONS 1. What kind of medicine do you take when you have a headache or fever? 2. Do you ever take aspirin? If so, what do you take it for? 3. Do you know what aspirin was first made from?
More informationGOFALU AM BOBL, CADW POBL YN IACH CARING FOR PEOPLE, KEEPING PEOPLE WELL. Cardiff & Vale HealthCharity ElusenIechyd Caerdydd a r Fro
SSTAFF RECOGNITION AWARDS 2018 Cardiff & Vale HealthCharity ElusenIechyd Caerdydd a r Fro GOFALU AM BOBL, CADW POBL YN IACH CARING FOR PEOPLE, KEEPING PEOPLE WELL STAFF RECOGNITION AWARDS 2018 WELCOME
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationExamining the relationship between beverage intake and cardiovascular health. Ian Macdonald University of Nottingham UK
Examining the relationship between beverage intake and cardiovascular health Ian Macdonald University of Nottingham UK Outline Assessment of evidence in relation to health risks of dietary components Cardiovascular
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationAntithrombotics 201: Aspirin and USPSTF. Presented by: Craig Williams, PharmD., BCPS., FNLA; November, Conflicts of Interest: None
Antithrombotics 201: Aspirin and USPSTF Presented by: Craig Williams, PharmD., BCPS., FNLA; November, 2016 Conflicts of Interest: None 1 What percent of patients who die within 30 days of an MI die before
More informationASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage and Louise Bowman on behalf of the ASCEND Study
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationEAS Congress Innsbruck Highlights: A programme to excite, inspire and inform!
Press release 84 th European Atherosclerosis Society Congress, Innsbruck, Austria For circulation 29 th May, 2016. 84 th Annual Congress of the European Atherosclerosis Society (EAS) May 29 th - June 1
More informationControversies in Preventative Cardiology
Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationToday, these are all common knowledge, especially in this wonderful age of the Internet, where Dr. Google is on-call 24/7.
MY column on Aspirin, the Wonder Drug came out in 2002 when this common household item was on the spotlight for sometime for its new role in staving off heart attack, medically termed Acute Myocardial
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationFaces of Wellness. Kent State University Bateman Gold Team. Latisha Ellison Daniel Henderson Taylor Pierce Lauryn Rosinski Rachel Stevenson
Faces of Wellness Kent State University Bateman Gold Team Latisha Ellison Daniel Henderson Taylor Pierce Lauryn Rosinski Rachel Stevenson Timothy Roberts, Faculty Advisor Lyndsey Fortunato, Professional
More informationigh-sensitivity Cardiac Troponin - A Canadian Viewpoint from CIHR funded studies Friday May 30, 2014
8:50-9:00 Welcome and Introduction Juravinski Cancer Center Lecture Theatre (4 th floor) 699 Concession St. Hamilton, ON L8V 5C2 Introduction to High-Sensitivity Cardiac Troponin Current State 9:00-9:45
More informationFrom the director. Joe V. Selby, MD, MPH
For 50 years, the Division of Research has been a central component in Kaiser Permanente s commitment to be a learning organization, dedicated to understanding and improving the health of Kaiser Permanente
More informationSponsorship opportunities 2018
Sponsorship opportunities 2018 11-13 September 2018 Edingburgh Assembly Rooms 54 George Street Edinburgh EH2 2LR Winners announced: 13 September 2018 Sheraton Grand Hotel Edinburgh About the annual seminar
More informationThe Journey towards Total Wellbeing A Health System s Innovative Approach
The Journey towards Total Wellbeing A Health System s Innovative Approach Company Profile Wellness A state of complete physical, mental and social wellbeing and not merely the absence of disease or infirmity
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationDimensions Self Assessment Report
Dimensions Self Assessment Report Driving up Quality Code How we self-assessed: We held several events in different parts of the country over many months to get a true picture of what everybody thinks
More informationSUNDAY, MARCH 24 TUESDAY, MARCH 26, 2019 THE MAYFLOWER HOTEL, WASHINGTON, DC 20 Y E A R S CELEBRATING 20 YEARS OF QUALITY
SUNDAY, MARCH 24 TUESDAY, MARCH 26, 2019 THE MAYFLOWER HOTEL, WASHINGTON, DC 20 Y E A R S 1999-2019 CELEBRATING 20 YEARS OF QUALITY TOPICS AND THEMES FOR 2019 Behavioral Health and Improving Care for Serious
More informationTribute to Chris Rainsford
RTST Newsletter 2014 Tribute to Chris Rainsford The Road Trauma Support Team of SA committee, families and friends pay tribute to our very popular and highly respected Counsellor, Mr Christopher Richard
More informationORIGINAL INVESTIGATION. An Update on Aspirin in the Primary Prevention of Cardiovascular Disease
ORIGINAL INVESTIGATION An Update on in the Primary Prevention of Cardiovascular Disease Rachel S. Eidelman, MD; Patricia R. Hebert, PhD; Steven M. Weisman, PhD; Charles H. Hennekens, MD, DrPH Background:
More informationModule 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town
Module 5 The Epidemiological Basis of Randomised Controlled Trials Landon Myer School of Public Health & Family Medicine, University of Cape Town Introduction The Randomised Controlled Trial (RCT) is the
More informationExecutive Director s. Update
Executive Director s Update February 2013 Mission, Vision and Values Toastmasters International Mission Vision Values Toastmasters International s core values are integrity, dedication to excellence,
More informationREVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationFLUOR LIMITED GENDER PAY GAP REPORT 2017
FLUOR LIMITED GENDER PAY GAP REPORT 2017 FLUOR GENDER PAY GAP REPORT 2017 Hiring the right people is critical to our success. In the UK, we are working to create a balanced workforce and supporting government
More informationMyocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD
Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationStrategy Sports Grounds Safety Authority Updated February 2018
Strategy 2016-2021 Sports Grounds Safety Authority Updated February 2018 Chair s Foreword The last year has seen many changes for the Sports Grounds Safety Authority (SGSA), welcoming me as the new Chair
More informationGUIDELINES FOR SCHOOL PEER GUIDE CO-ORDINATORS
GUIDELINES FOR SCHOOL PEER GUIDE CO-ORDINATORS These guidelines should be read in conjunction with the Code of Practice for the Peer Guide Scheme and the Guidelines for Peer Guides and Potential Peer Guides.
More information31 October 2017 AIM: RENE. ReNeuron Group plc ( ReNeuron or the Company ) Positive stroke clinical data & regulatory update
31 October 2017 AIM: RENE ReNeuron Group plc ( ReNeuron or the Company ) Positive stroke clinical data & regulatory update Long term data from Phase II stroke clinical trial confirm positive results seen
More informationCHANGING COURSE: ANTICOAGULATION IN SECONDARY PREVENTION OF CAD
Earn up to 1.0 CME credit CHANGING COURSE: ANTICOAGULATION IN SECONDARY PREVENTION OF CAD THURSDAY, APRIL 26, 2018 11:45 am 12:15 pm Registration and Buffet Lunch 12:15 pm 1:15 pm CME Symposium MANCHESTER
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationCalculating Risk for Primary Prevention of Cardiovascular Disease (CVD)
Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) 2. Welcome by Stacey Sheridan, MD, MPH Hello. My name is Stacey Sheridan, and I m here as your partner in Heart Health Now. The North
More informationComponent 2: The Culture of Health Care. Overview. Definitions and operationalization
Component 2: The Culture of Health Care Unit 7: Quality Measurement, Performance Improvement, and Incentive Payment Schemes Lecture 2 This material was developed by Oregon Health & Science University,
More informationRivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional
More informationThis booklet has been published by CREST (the Clinical Resource Efficiency Support Team).
This booklet has been published by CREST (the Clinical Resource Efficiency Support Team). CREST is a small committee of health care professionals established under the auspices of the Central Medical Advisory
More informationBayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary
More informationIs a Mediterranean diet best for preventing heart disease?
Is a Mediterranean diet best for preventing heart disease? By Peter Attia, M.D. This week an article titled Primary Prevention of Cardiovascular Disease with a Mediterranean Diet was featured in the New
More informationLow HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
More information26 January 2018 AIM: RENE RNS REACH. ReNeuron Group plc ( ReNeuron or the Company ) Phase II stroke data presented at AHA conference
26 January 2018 AIM: RENE RNS REACH ReNeuron Group plc ( ReNeuron or the Company ) Phase II stroke data presented at AHA conference Positive long-term data from Phase II stroke disability clinical trial
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationInformation pack. Thank you. for Being Co-op awards
Information pack Thank you for Being Co-op awards What are the Thank you for Being Co-op awards? We need your nominations! We re on the hunt for those brilliant colleagues who spread a little Co-op magic
More information2017 President s club Rewards + Recognition Program
ALL ABOARD! 2017 President s club Rewards + Recognition Program CAMPAIgn 1, 2017 to campaign 18, 2017 Welcome to the 2017 President s Club Program. I would like to express my sincere gratitude to you,
More informationEvidenceNOW SW Learning Collaborative. Kyle Knierim, MD January 2017
EvidenceNOW SW Learning Collaborative Kyle Knierim, MD January 2017 What is cardiovascular disease? Why are we even talking about cardiovascular disease? What can we do to prevent and treat cardiovascular
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More informationCANDIDATE PACK. Trustee
CANDIDATE PACK Trustee Candidate Pack 2014 Background Information Introduction The Motor Neurone Disease (MND) Association is the only national charity in England, Wales and Northern Ireland that funds
More informationIntroduction; Study design
; Study design Patrick Breheny January 12 Patrick Breheny STA 580: Biostatistics I 1/43 What is statistics? What is biostatistics, and why is it important? The statistical framework Statistics is the science
More informationWomen s Homeless Health - In Reach Volunteer Homeless Health - In Reach Volunteer Homeless Health Peer Advocacy Service (HHPA)
Super Duper Mega Volunteering Pack 1 Ever been homeless? Interested in volunteering? If so. We have a lot of different opportunities waiting for you!!! Women s Homeless Health - In Reach Volunteer Homeless
More informationJeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine.
Jeff Balser, M.D., Ph.D., President and CEO of Vanderbilt University Medical Center, and Dean, Vanderbilt University School of Medicine. 1 2 On April 30 the VU and VUMC transition was completed and we
More informationCARDIOVASCULAR HEALTH LIVING A HEART HEALTHY LIFE. Matt Handley MD Group Health Physicians
CARDIOVASCULAR HEALTH LIVING A HEART HEALTHY LIFE Matt Handley MD Group Health Physicians WILLIE SUTTON Add together your risk of dying from breast cancer and colon cancer (women), or prostate cancer and
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationDietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women
07/14/2010 Dietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women First Author: Wang Short Title: Dietary Fatty Acids and Hypertension Risk in Women Lu Wang, MD, PhD, 1 JoAnn E.
More informationUpdate on the Million Veteran Program Opportunities for Collaboration with WHI T. L. Assimes, MD PhD FAHA
Update on the Million Veteran Program Opportunities for Collaboration with WHI T. L. Assimes, MD PhD FAHA Associate Professor of Medicine, Stanford University Associate Director, Palo Alto VA Health Care
More informationMULTINATIONAL HEART FAILURE STUDY SHOWS HIGH PREVALENCE OF CORONARY ARTERY DISEASE, HYPERTENSION AND DIABETES IN ASIAN PATIENTS
MEDIA RELEASE 16 June 2016 MULTINATIONAL HEART FAILURE STUDY SHOWS HIGH PREVALENCE OF CORONARY ARTERY DISEASE, HYPERTENSION AND DIABETES IN ASIAN PATIENTS A multinational study involving over 5,000 heart
More informationDigestive & Metabolic Diseases
4 th World Congress on Digestive & Metabolic Diseases October 29-30, 2018 San Francisco, California, USA Invitation Dear Attendees, We are glad to announce the 4 th World Congress on Digestive & Metabolic
More informationSponsorship Package. June 2016
Sponsorship Package June 2016 Jillian Huth Relay For Life Coordinator, South West Queensland T: 07 4690 5816 M: 0457 384 961 jillianhuth@cancerqld.org.au www.cancerqld.org.au June 2016 Dear We are currently
More informationHarry Stevenson, President, Social Work Scotland. Annual Conference and Exhibition 18 and 19 June 2014
Harry Stevenson, President, Social Work Scotland Annual Conference and Exhibition 18 and 19 June 2014 It is a great privilege to give the address to conference as first president of Social Work Scotland
More informationStatement from the Steering Committee of the Alzheimer s Disease Anti inflammatory Prevention Trial (ADAPT)
Statement for FDA Joint Advisory Committee page 1 Statement from the Steering Committee of the Alzheimer s Disease Anti inflammatory Prevention Trial (ADAPT) for communication to the FDA Arthritis Advisory
More informationWOMEN S CARDIOVASCULAR HEALTH. Northwestern s Bluhm Cardiovascular Institute Center for Preventive Cardiology
WOMEN S CARDIOVASCULAR HEALTH Northwestern s Bluhm Cardiovascular Institute Center for Preventive Cardiology Program for Women s Cardiovascular Health WOMEN S CARDIOVASCULAR HEALTH Northwestern s Bluhm
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More information600 guests , TV broadcast. Collaboration opportunities Contact: David Bell NEWS stories TEAMS
200,000+ BRANDED EMAILS SENT 17 patient representatives 1 TV broadcast 1,276 tweets on awards night 43 EXPERT JUDGES 21 regional NEWS stories 300+ ENTRIES 600 guests 2018 Collaboration opportunities Contact:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationACADEMIA EUROPAEA CARDIFF KNOWLEDGE HUB HALF-YEAR REPORT 2017
ACADEMIA EUROPAEA CARDIFF KNOWLEDGE HUB HALF-YEAR REPORT 2017 1 Introduction By Professor Ole Petersen CBE FMedSci FLSW MAE ML FRS Honorary Academic Director, Academia Europaea Cardiff Knowledge Hub Highlights
More information